Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective studyof 126 patients

Mobilization techniques for peripheral blood stem cell (PBSC) collection in clude the administration of chemotherapy followed by hematopoietic growth f actors or growth factors alone, Two forms of recombinant human granulocyte colony-stimulating factor (rhG-CSF) are available for PBSC mobilization: le nograstim and filgrastim which are the glycosylated and non-glycosylated fo rms respectively. In order to determine the influence of the two forms of G -CSF following chemotherapy on PBSC collection, we conducted a retrospectiv e study in 126 patients with various hematological malignancies: 65 and 61 for the lenograstim and filgrastim groups respectively, No significant diff erences between the two groups were observed in terms of sex, age and diagn osis. Prior therapies and PBSC mobilization regimen were also equivalent, N o significant difference was observed between the groups for the median CD3 4+ cells harvested. The number of leukapheresis necessary to obtain a minim al number of 3 x 10(6) CD34+ cells/kg was equivalent for the two groups. Th e proportion of patients affected by a failure in PBSC collection was simil ar in the two groups. Our data suggest that lenograstim and filgrastim are equivalent for PBSC mobilization after chemotherapy.